Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, describes the Barcelona baseline risk score (Barcelona_BRS), a technique used to predict long-term prognosis in patients with multiple sclerosis (MS). This score integrates factors such as age, sex, the topography of the first attack, lesion number and topography, biomarkers and allows stratifying patients into three prognostic categories. Each category has a different pattern of atrophy, progression, relapse, quality of life (QoL), and Expanded Disability Status Scale (EDSS) trajectory. This interview took place during the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Vienna, Austria.
Dr Tintoré has received compensation for:
Consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Jansen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals.
Receipt grants and research supports from Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000. Biogen-Idec, Novartis.